
Anke Reinacher-Schick was involved in the study.
Photo Credit: © Jakob Studnar
Scientific Frontline: Extended "At a Glance" Summary: Immunotherapy for Stage III Colon Cancer
The Core Concept: A highly effective clinical protocol that combines the immunotherapy atezolizumab (Tecentriq®) with standard adjuvant FOLFOX chemotherapy to treat patients with resected stage III colon cancer exhibiting deficient DNA mismatch repair (dMMR).
Key Distinction/Mechanism: Unlike conventional treatments that rely solely on cytotoxic mechanisms, this protocol integrates immunotherapy to target a biologically distinct, early-stage cancer subgroup. The addition of atezolizumab bolsters the immune system's response to dMMR tumors, resulting in a 50 percent reduction in the risk of disease recurrence or death compared to standard chemotherapy alone.
Major Frameworks/Components:
- Atezolizumab (Tecentriq®): The primary immunotherapeutic agent utilized to enhance the immune response.
- FOLFOX Chemotherapy: The established adjuvant chemotherapy regimen used as the baseline therapeutic foundation.
- Deficient DNA Mismatch Repair (dMMR): The specific genetic and biological biomarker identifying the patient subgroup eligible for this combined therapy.
- Phase III Alliance ATOMIC A021502 Trial: The global, multi-institutional clinical trial that verified the efficacy of the treatment protocol.


.jpg)

.jpg)



.jpg)


.jpg)
